Towards disease modifying therapies of neurodegenerative diseases
Research report (imported) 2016 - Max Planck Institute for Multidisciplinary Sciences
Neurodegenerative diseases‘ hallmark is the aggregation of mostly intrinsically disordered proteins. Getting fundamental insights into the structural biology of these proteins, it was possible to identify oligomers as an attractive target for disease modifying therapies. The compound anle138b is bearing the required properties regarding modification of aggregation pathways, and is also orally bioavailable.